Lancashire and South Cumbria
Formulary
Formulary
4 Central nervous system
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
04-06 Domperidone and metoclopramide
| Metoclopramide |
|
First Choice
|
| Tablets 10mg Liquid 5mg/5ml Injection 10mg/2mL Metoclopramide may induce acute dystonic reactions and should be avoided in patients under 20 years – see BNF Risk of neurological adverse effect – restricted dose and duration of use. Maximum adult dose is 30mg daily. Should only be prescribed for short term us (up to 5 days) NB/ advice does not apply to unlicensed uses of metoclopramide (e.g. palliative care). |
 MHRA: Metoclopramide: risk of neurological adverse effects |
|
| Domperidone |
|
Second Choice
|
Tablets 10mg Domperidone is now authorised for the relief of symptoms of nausea and vomiting only in adults and adolescents 12 years of age or older and weighing 35kg or more. Consider alternative treatments to domperidone in children younger than 12 years of age who need relief of symptoms of nausea and vomiting.
|
|
MHRA: Domperidone: risks of cardiac side effects |
|
|
in paediatricsLinks
- Hypersalivation – can hyoscine hydrobromide be used to treat it?
- Hypersalivation treatment options
- MHRA Drug Safety Update April 2016: Apomorphine with domperidone: minimising risk of cardiac side effects
- MHRA Drug Safety Update Dec 2019: Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents
- MHRA Dug Safety Update Jan 2020: Ondansetron in pregnancy – small increased risk of oral clefts following use in the first 12 weeks of pregnancy
- MHRA update on restricted dose information (Aug 13)
- MHRA: Advice for domperidone (April 2014)
- MHRA: Domperidone: risks of cardiac side effects
- MHRA: Metoclopramide: risk of neurological adverse effects
- MHRA: Ondansetron: small increased risk of oral clefts following use in the first 12 weeks of pregnancy
- NICE CG150: Headaches in over 12s: diagnosis and management
- NICE CG84: Diarrhoea and vomiting caused by gastroenteritis in under 5s: diagnosis and management
- NICE TA:919 Rimegepant for treating migraine
- NICE TA906: Rimegepant for preventing migraine
- NICE TA919: Rimegepant for treating migraine
- NICE TA973: Atogepant for preventing migraine
- NICE: Management of vomiting in children and young people with gastroenteritis: ondansetron
- Ondansetron for vomiting in children with gastroenteritis- NICE evidence summary
UKMI: Domperidone - New restrictions in GI conditions (May 2014)